KR20160124829A - 노르이보가인 및 관련된 화합물을 이용하는 치료 방법 - Google Patents

노르이보가인 및 관련된 화합물을 이용하는 치료 방법 Download PDF

Info

Publication number
KR20160124829A
KR20160124829A KR1020167025602A KR20167025602A KR20160124829A KR 20160124829 A KR20160124829 A KR 20160124829A KR 1020167025602 A KR1020167025602 A KR 1020167025602A KR 20167025602 A KR20167025602 A KR 20167025602A KR 20160124829 A KR20160124829 A KR 20160124829A
Authority
KR
South Korea
Prior art keywords
patient
pharmaceutically acceptable
acceptable salt
solvate
dose
Prior art date
Application number
KR1020167025602A
Other languages
English (en)
Korean (ko)
Inventor
로렌스 프리드호프
에믈라인 말렛
홀거 와이스
Original Assignee
데메알엑스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/019692 external-priority patent/WO2015126434A1/fr
Priority claimed from US14/195,822 external-priority patent/US9345711B2/en
Priority claimed from US14/485,514 external-priority patent/US20150231147A1/en
Application filed by 데메알엑스, 인크. filed Critical 데메알엑스, 인크.
Publication of KR20160124829A publication Critical patent/KR20160124829A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • Y10S514/81—
    • Y10S514/811—
    • Y10S514/813—

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167025602A 2014-02-18 2015-02-17 노르이보가인 및 관련된 화합물을 이용하는 치료 방법 KR20160124829A (ko)

Applications Claiming Priority (45)

Application Number Priority Date Filing Date Title
US201461941387P 2014-02-18 2014-02-18
US201461941390P 2014-02-18 2014-02-18
US61/941,387 2014-02-18
US61/941,390 2014-02-18
US201461945746P 2014-02-27 2014-02-27
US61/945,746 2014-02-27
WOPCT/US2014/019692 2014-02-28
PCT/US2014/019692 WO2015126434A1 (fr) 2014-02-18 2014-02-28 Méthodes de traitement aigu et à long terme de la toxicomanie
US14/195,822 2014-03-03
US14/195,822 US9345711B2 (en) 2014-02-18 2014-03-03 Methods for acute and long-term treatment of drug addiction
US201461952731P 2014-03-13 2014-03-13
US201461952741P 2014-03-13 2014-03-13
US201461952733P 2014-03-13 2014-03-13
US201461952738P 2014-03-13 2014-03-13
US201461952744P 2014-03-13 2014-03-13
US201461952727P 2014-03-13 2014-03-13
US61/952,733 2014-03-13
US61/952,738 2014-03-13
US61/952,731 2014-03-13
US61/952,741 2014-03-13
US61/952,727 2014-03-13
US61/952,744 2014-03-13
US201462005858P 2014-05-30 2014-05-30
US201462005841P 2014-05-30 2014-05-30
US201462005855P 2014-05-30 2014-05-30
US201462005851P 2014-05-30 2014-05-30
US201462005847P 2014-05-30 2014-05-30
US62/005,858 2014-05-30
US62/005,851 2014-05-30
US14/292,632 2014-05-30
US62/005,855 2014-05-30
US14/292,632 US20150231146A1 (en) 2014-02-18 2014-05-30 Methods for acute and long-term treatment of drug addiction
US62/005,847 2014-05-30
US62/005,841 2014-05-30
US201462007346P 2014-06-03 2014-06-03
US62/007,346 2014-06-03
US201462024388P 2014-07-14 2014-07-14
US62/024,388 2014-07-14
US201462033538P 2014-08-05 2014-08-05
US62/033,538 2014-08-05
US201462035335P 2014-08-08 2014-08-08
US62/035,335 2014-08-08
US14/485,514 US20150231147A1 (en) 2014-02-18 2014-09-12 Methods for acute and long-term treatment of drug addiction
US14/485,514 2014-09-12
PCT/US2015/016186 WO2015126836A2 (fr) 2014-02-18 2015-02-17 Méthodes thérapeutiques faisant intervenir de la noribogaïne et des composés apparentés

Publications (1)

Publication Number Publication Date
KR20160124829A true KR20160124829A (ko) 2016-10-28

Family

ID=53879225

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167025602A KR20160124829A (ko) 2014-02-18 2015-02-17 노르이보가인 및 관련된 화합물을 이용하는 치료 방법

Country Status (10)

Country Link
EP (1) EP3107546A4 (fr)
JP (1) JP2017506244A (fr)
KR (1) KR20160124829A (fr)
CN (1) CN106413718A (fr)
AU (2) AU2015219172A1 (fr)
CA (2) CA3221251A1 (fr)
EA (1) EA201691656A2 (fr)
IL (1) IL247325A0 (fr)
TW (1) TW201534306A (fr)
WO (1) WO2015126836A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143201A1 (fr) 2013-03-15 2014-09-18 Demerx, Inc. Procédé pour le traitement avec la noribogaïne de l'addiction de patients sous méthadone
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
EP3915639B1 (fr) * 2014-11-26 2023-06-07 DemeRx, Inc. Procédés et compositions pour potentialiser l'action d'analgésiques opioïdes en utilisant des alcaloïdes de l'iboga

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE324897T1 (de) * 1994-07-25 2006-06-15 Nda Int Inc Verwendung von noribogain derivaten zur behandlung von chemischer abhängigkeit bei säugern
EP1327447B1 (fr) * 1997-09-04 2011-05-25 Novoneuron, Inc. Noribogaine utilisée pour le traitement de la douleur et de la toxomanie
US7220737B1 (en) * 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
US20030153552A1 (en) * 2002-02-14 2003-08-14 Mash Deborah C. Method of treating chemical dependency in mammals and a composition therefor
MX2013000733A (es) * 2010-07-23 2013-05-30 Demerx Inc Composiciones de noribogaina.
WO2014143201A1 (fr) * 2013-03-15 2014-09-18 Demerx, Inc. Procédé pour le traitement avec la noribogaïne de l'addiction de patients sous méthadone

Also Published As

Publication number Publication date
CA2977636A1 (fr) 2015-08-27
WO2015126836A2 (fr) 2015-08-27
CA2977636C (fr) 2024-01-02
AU2020267217A1 (en) 2020-12-03
EP3107546A2 (fr) 2016-12-28
AU2015219172A1 (en) 2016-09-29
CN106413718A (zh) 2017-02-15
EP3107546A4 (fr) 2017-10-25
TW201534306A (zh) 2015-09-16
JP2017506244A (ja) 2017-03-02
AU2020267217B2 (en) 2022-04-07
IL247325A0 (en) 2016-09-29
CA3221251A1 (fr) 2015-08-27
EA201691656A2 (ru) 2017-03-31

Similar Documents

Publication Publication Date Title
AU2020273281B2 (en) Therapeutic uses of ibogaine and related compounds
AU2020267217B2 (en) Therapeutic methods employing noribogaine and related compounds
JP2009509975A (ja) 薬物嗜癖および行動嗜癖を治療するためのイブジラストの使用
SK3732003A3 (sk) Spôsob analgézie
US11077118B2 (en) Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
Schumacher et al. Basic and clinical pharmacology
Jenkins et al. Pharmacokinetics: drug absorption, distribution and elimination
JPS59501459A (ja) カフェインを含んで成る改良された鎮痛及び抗炎症組成物並びにその使用方法
US20150110865A1 (en) Cns stimulant and opioid receptor antagonist combination as a non-addictive, non-aversive and synergistic anti-obesity treatment
Nicholson et al. Modulation of catecholamine transmission and sleep in man
US20160038505A1 (en) Methods and compositions for treating impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
KR20220113411A (ko) KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도
CN116440140A (zh) 用于在涉及炎性反应的疼痛状态中镇痛的外周限制的双效κ和δ阿片样物质激动剂
JP7406266B2 (ja) 鎮痛組成物
CN112569355B (zh) 伊马替尼及其衍生物与成瘾物质联合用药或复方制剂在预防、治疗成瘾及防治复吸中的应用
Wouden et al. General anesthetic pharmacology
Stäuble et al. Anatomy and Physiology, Paralytics, and Reversal Agents
Mellon The neurotoxic potential of opioids including fentanyl and fentanyl analogs
Li et al. Methadone Usage, Misuse, and Addiction Processes: An Overview
CN115942979A (zh) 在减少阿片类物质使用的治疗中使用的mglur5拮抗剂玛沃谷兰
WO2007039869A2 (fr) Utilisation de la neboglamine dans le traitement de la toxicodependance
Dorp an.(2009, une 24)
WO2009097414A1 (fr) Utilisation d'imidazolylalkyl-pyridines pour le traitement de troubles addictifs
JP2005255695A (ja) 慢性疼痛の治療のための医薬の製造に有用な組成物